DE59510742D1 - Nukleoside und Oligonukleotide mit 2'-Ethergruppen - Google Patents

Nukleoside und Oligonukleotide mit 2'-Ethergruppen

Info

Publication number
DE59510742D1
DE59510742D1 DE59510742T DE59510742T DE59510742D1 DE 59510742 D1 DE59510742 D1 DE 59510742D1 DE 59510742 T DE59510742 T DE 59510742T DE 59510742 T DE59510742 T DE 59510742T DE 59510742 D1 DE59510742 D1 DE 59510742D1
Authority
DE
Germany
Prior art keywords
formula
nucleosides
oligonucleotides
ether groups
protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59510742T
Other languages
English (en)
Inventor
Dr Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE59510742D1 publication Critical patent/DE59510742D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DE59510742T 1994-04-27 1995-04-19 Nukleoside und Oligonukleotide mit 2'-Ethergruppen Expired - Lifetime DE59510742D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH130794 1994-04-27

Publications (1)

Publication Number Publication Date
DE59510742D1 true DE59510742D1 (de) 2003-08-14

Family

ID=4207379

Family Applications (1)

Application Number Title Priority Date Filing Date
DE59510742T Expired - Lifetime DE59510742D1 (de) 1994-04-27 1995-04-19 Nukleoside und Oligonukleotide mit 2'-Ethergruppen

Country Status (15)

Country Link
US (2) US5750673A (de)
EP (1) EP0679657B1 (de)
JP (1) JPH07300493A (de)
KR (1) KR950032263A (de)
CN (1) CN1066456C (de)
AT (1) ATE244723T1 (de)
AU (1) AU682576B2 (de)
CA (1) CA2147798A1 (de)
CY (1) CY2498B1 (de)
DE (1) DE59510742D1 (de)
DK (1) DK0679657T3 (de)
ES (1) ES2203635T3 (de)
IL (1) IL113482A0 (de)
PT (1) PT679657E (de)
ZA (1) ZA953383B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269870T1 (de) 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
ATE244723T1 (de) * 1994-04-27 2003-07-15 Novartis Pharma Gmbh Nukleoside und oligonukleotide mit 2'- ethergruppen
US6166197A (en) * 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH10512894A (ja) * 1995-03-06 1998-12-08 アイシス・ファーマシューティカルス・インコーポレーテッド ２’−ｏ−置換ピリミジンおよびそのオリゴマー化合物の合成の改良法
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
EP0839813A1 (de) * 1996-04-09 1998-05-06 Yamasa Corporation 9-(2-deoxy-2-fluor-4-thio-beta-d-arabinofuranosyl)purin-derivate
DK0906329T3 (da) 1996-06-06 2004-02-09 Novartis Ag 2'-Substituerede nukleosider og oligonukleotidderivater
NZ502642A (en) 1997-07-03 2002-06-28 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
FR2788524B1 (fr) * 1999-01-18 2002-04-26 Merial Sas Procede utile pour transformer la fonction 4"(s)-oh du motif cladinose d'un aza macrolide en 4"(r)-nh2
AR025996A1 (es) 1999-10-07 2002-12-26 Valigen Us Inc Plantas no transgenicas resistentes a los herbicidas.
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
EP1572097A4 (de) * 2002-09-30 2010-02-17 Smithkline Beecham Corp Nucleosid-derivate zur behandlung von infektionen mit dem hepatitis c-virus
KR100481356B1 (ko) * 2002-10-17 2005-04-07 이수화학 주식회사 2'-ｏ-치환된 뉴클레오시드의 제조 방법
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US7947817B2 (en) * 2003-06-30 2011-05-24 Roche Molecular Systems, Inc. Synthesis and compositions of 2'-terminator nucleotides
CA2543116A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
US7745125B2 (en) * 2004-06-28 2010-06-29 Roche Molecular Systems, Inc. 2′-terminator related pyrophosphorolysis activated polymerization
EP2923563A3 (de) 2006-01-12 2015-10-14 Cibus Europe B.V. EPSPS-Mutanten
RU2483057C2 (ru) 2006-06-28 2013-05-27 Ньюселис Инк. Смеси жирных кислот и их применение
US7820810B2 (en) * 2007-03-19 2010-10-26 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted purine nulceosides
US20090205064A1 (en) 2007-10-05 2009-08-13 Christian Schopke Mutated Acetohydroxyacid Synthase Genes in Brassica
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
UA108343C2 (uk) 2008-05-23 2015-04-27 Нуцеліс Інк. Спосіб одержання сквалену за допомогою дріжджів
JP5438922B2 (ja) * 2008-06-25 2014-03-12 日東電工株式会社 核酸の製造方法
PE20110383A1 (es) 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
CA2741294C (en) * 2008-10-24 2018-04-24 Isis Pharmaceuticals, Inc. 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
UA111813C2 (uk) 2009-11-23 2016-06-24 Нукеліс, Інк. Спосіб одержання сквалену з застосуванням дріжджів
UA112969C2 (uk) 2010-08-03 2016-11-25 Сібас Юс Ллс Рослина, стійка до одного або більше ррх-інгібуючих гербіцидів, яка містить мутантний ген протопорфіриноген ix оксидази (ррх)
US20120122223A1 (en) 2010-08-03 2012-05-17 Cibus Us Llc Mutated protoporphyrinogen ix oxidase (ppx) genes
CN103052639B (zh) 2010-08-12 2016-02-17 贝林格尔.英格海姆国际有限公司 6-环烷基-1,5-二氢-吡唑并[3,4-d]嘧啶-4-酮衍生物及其作为PDE9A抑制剂的用途
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN114703210A (zh) 2013-03-14 2022-07-05 希博斯美国有限公司 突变的丙二烯氧合酶2(aos2)基因
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
UA121099C2 (uk) 2013-03-15 2020-04-10 Сібас Юс Ллс Спосіб підвищення ефективності спрямованої модифікації генів із застосуванням опосередкованої олігонуклеотидами репарації генів
ES2921207T3 (es) 2013-03-15 2022-08-19 Cibus Us Llc Procedimientos y composiciones para aumentar la eficiencia de la modificación genética direccionada utilizando la reparación genética mediada por oligonucleótidos
CA3208184A1 (en) 2014-03-14 2015-09-17 Cibus Us Llc Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
BR112018016278A2 (pt) 2016-02-09 2019-01-02 Cibus Europe Bv métodos e composições para aumentar a eficiência da modificação do gene direcionada usando reparação de gene mediada por oligonucleotídeo
JP2019525916A (ja) 2016-07-27 2019-09-12 ロシュ イノベーション センター コペンハーゲン エーエス ５’ｓ−ｌｎａヌクレオチドおよびオリゴヌクレオチド
WO2018165564A1 (en) 2017-03-09 2018-09-13 Ionis Pharmaceuticals, Inc. Morpholino modified oligomeric compounds
US11359208B2 (en) 2018-01-09 2022-06-14 Cibus Us Llc Shatterproof genes and mutations
WO2021030778A1 (en) 2019-08-15 2021-02-18 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (de) * 1986-10-28 1990-09-19 The Johns Hopkins University Alkyl- oder Arylphosphonat-Oligonukleosid, das sich mit Nukleinesäuren vernetzen kann oder das Nukleinsäure spalten kann
ATE132190T1 (de) * 1988-02-26 1996-01-15 Worcester Found Ex Biology Hemmung von htlv-iii durch exogene oligonukleotide
JPH0372493A (ja) * 1989-08-10 1991-03-27 Kikkoman Corp ２´―ｏ―置換―アデノシン―３´，５´―環状リン酸又はその塩の製法
ATE269870T1 (de) * 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
US5506351A (en) * 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
DE4037363A1 (de) * 1990-04-09 1991-10-10 Europ Lab Molekularbiolog 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten
JPH06256380A (ja) * 1993-03-09 1994-09-13 Toagosei Chem Ind Co Ltd ヌクレオシド誘導体ならびにリンカーを有するヌクレオシド誘導体の合成方法
EP0626387B1 (de) * 1993-05-12 1999-03-10 Novartis AG Nukleoside und Oligonukleotide mit 2'-Ethergruppen
DE4317323A1 (de) * 1993-05-25 1994-12-01 Bayer Ag N-(4-Fluor-phenyl)-heteroaryloxyacetamide
ATE244723T1 (de) * 1994-04-27 2003-07-15 Novartis Pharma Gmbh Nukleoside und oligonukleotide mit 2'- ethergruppen

Also Published As

Publication number Publication date
IL113482A0 (en) 1995-07-31
ZA953383B (en) 1995-10-27
AU1765395A (en) 1995-11-02
EP0679657B1 (de) 2003-07-09
EP0679657A3 (de) 1996-04-10
CN1115320A (zh) 1996-01-24
DK0679657T3 (da) 2003-10-27
AU682576B2 (en) 1997-10-09
EP0679657A2 (de) 1995-11-02
CY2498B1 (en) 2005-09-02
US5750673A (en) 1998-05-12
PT679657E (pt) 2003-11-28
ATE244723T1 (de) 2003-07-15
CN1066456C (zh) 2001-05-30
ES2203635T3 (es) 2004-04-16
JPH07300493A (ja) 1995-11-14
US5977332A (en) 1999-11-02
KR950032263A (ko) 1995-12-20
CA2147798A1 (en) 1995-10-28

Similar Documents

Publication Publication Date Title
DE59510742D1 (de) Nukleoside und Oligonukleotide mit 2'-Ethergruppen
ATE541576T2 (de) 2'-o,4'-c-methylen bicyclonukleoside
GR3023432T3 (en) Oligonucleotide analogues with terminal 3'-3' or 5'-5'-internucleotide linkages
NZ335397A (en) Immunostimulatory unmethylated CpG dinucleotides
GB9716231D0 (en) Base analogues
ES2127948T3 (es) Oligonucleotidos modificados en la posicion 2'-amido y 2'-peptido.
DE69333344T2 (de) Neue 2'-0-Alkyl-Nukleoside und Phosphoramidite, Verfahren zu deren Herstellung und deren Verwendung
IL100298A (en) 3(-(2()-amino- or thiol- modified, fluorescent dye- coupled nucleosides, nucleotides and oligonucleotides, and a process for the preparation and the use thereof
EP0663922A1 (de) Infrarot-farbstoff-markierte nucleotide und ihre verwendung in der nucleinsäure-detektion
CA2278715A1 (en) Aminooxy-modified oligonucleotides
ATE124412T1 (de) Antivirusderivate von (phosphonmethoxy)methoxy purin/pyrimidin.
FI932870A (fi) 2'-deoxi-2'2'-difluor-(4-substituerad pyrimidin)nukleosider med virus-och cancerhaemmande aktivitet, samt mellanprodukter
DE69024804D1 (de) Antivirale zusammensetzung
ATE371740T1 (de) Phosphodiesterasen
DE69632830D1 (de) Rezeptor und dafür kodierendes nukleinsäuremolekül
ES2052789T3 (es) Dna con el gen de resistencia a compuestos analogos a pirimidina y su uso.
GB9506644D0 (en) Preparation of nucleoside analogues
Jun et al. The enzymatic properties of extracellular adenine deaminase from Streptomyces sp. J-350P

Legal Events

Date Code Title Description
8364 No opposition during term of opposition